Тобразон

Quick links to important sections

Тобразон

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Тобразон

Property Description
Active Ingredients Dexamethasone, Tobramycin
Form Sterile Ophthalmic Suspension (Eye Drops) / Ointment
Pharmacological Class Ophthalmic Steroids with Anti-infectives
General Purpose Management of Ocular Inflammation and Bacterial Threat
Origin Type Fixed-Dose Combination (Synthetic and Semisynthetic Components)

Defining the Combination Ophthalmic Agent

Тобразон is a prescription-only, fixed-dose combination medication for topical ocular administration, formally classified as an Ophthalmic Steroid with Anti-infectives. This dual-component medicine is primarily supplied as a sterile ophthalmic suspension (eye drops) or sterile ophthalmic ointment. This structure is clinically recognized for its therapeutic efficacy in settings where both components are needed. The fixed-dose design is a differentiating feature from single-agent formulations, ensuring that both inflammatory symptoms and potential bacterial components of an eye condition are addressed simultaneously.

Composition: Dexamethasone and Tobramycin

The active core of Тобразон comprises two distinct compounds: Dexamethasone and Tobramycin. Dexamethasone is identified as a potent, synthetic corticosteroid (glucocorticoid) intended to provide the anti-inflammatory component. The second compound, Tobramycin, is an aminoglycoside antibiotic derived from natural or semisynthetic sources. This combination of a potent steroid and an antibiotic is standard in formulations (e.g., TobraDex), demonstrating the therapeutic value of pairing these two distinct pharmacological actions.

General Purpose of the Dual-Action Formula

The general therapeutic purpose of this dual-action formula is the simultaneous management of ocular inflammation and the corresponding bacterial threat. The Dexamethasone component provides a rapid and powerful anti-inflammatory effect to reduce associated redness, swelling, and discomfort. Concurrently, the Tobramycin component exerts its targeted antibacterial action, which is effective against common ocular pathogens. This fixed combination minimizes the risk that steroid-induced immunosuppression could worsen an existing infection, ensuring that anti-inflammatory relief and infection control proceed together efficiently in situations like post-surgical prophylaxis or acute inflammatory episodes.

Regulatory References

  1. FDA Drug Label for Tobramycin

What side effects are possible with Тобразон?

Possible Side Effects and Safety Information

The safety profile of this ophthalmic combination is primarily based on officially documented adverse reactions classified by frequency and association with specific body systems. The majority of reported effects relate to the eye.

Frequency-Classified Ocular Reactions

Adverse reactions are organized by occurrence rates consistent with regulatory standards (e.g., EMA/ICH classification):

Frequency Classification Associated Adverse Reactions (Examples)
Common Ocular discomfort, eye pain, eye pruritus (itching), eye hyperemia (redness).
Uncommon Increased intraocular pressure (IOP), punctate keratitis (small defects on cornea), blurred vision, headache.
Rare Hypersensitivity reactions, visual field defect.

Duration-Dependent Serious Risks

Regulatory documents emphasize that the most clinically significant risks are linked to the duration of exposure. Prolonged or extended use of the corticosteroid component is officially associated with the potential for developing Increased Intraocular Pressure (IOP), which may lead to glaucoma, and the formation of posterior subcapsular cataracts. In individuals with pre-existing thinning of the cornea or sclera, the use of topical steroids carries a documented risk of perforation.

Population and Safety Constraints

The official label states that safety and effectiveness have not been established in pediatric patients under two years of age. Furthermore, a safety restriction notes that if this product is used for ten days or longer, intraocular pressure monitoring is mandatory. A high-level safety caution exists for concomitant use with systemic aminoglycoside antibiotics due to the potential for cumulative toxicity.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation defines the profile for an overdose of this combination ophthalmic product based on the route and amount of exposure.

Documented Overdose Manifestations

Over-application to the eye is documented to present with local ocular effects that may be similar to known adverse reactions. These local manifestations include punctate keratitis, erythema (redness), increased lacrimation (tearing), edema (swelling, specifically of the lid), and lid itching. In the event of such local over-application, immediately flushing the eye(s) with lukewarm water is the advised supportive measure.

Systemic Risk and Required Emergency Action

The potential for severe overdose, classified by a risk of systemic toxicity, is associated with the Tobramycin component if the medication is accidentally swallowed. Due to systemic absorption risks, such an event carries the potential for serious outcomes, including neurotoxicity, ototoxicity, and nephrotoxicity. Regulatory guidance mandates that if the product is accidentally ingested, emergency action must be taken immediately.

When Immediate Medical Help Is Required

Urgent medical help is required in the event of accidental swallowing of the medication. The official instruction is to seek emergency medical care immediately and contact the Poison Help Line or equivalent national emergency service. The official labeling confirms that no specific antidote is known for the topical formulation; therefore, management remains supportive and symptomatic.

Therapeutic Uses of Тобразон

The primary therapeutic purpose of this ophthalmic combination is the management of ocular inflammation and the risk of superficial bacterial infection. It may assist with providing symptomatic relief in areas where functional stability becomes affected. This use is considered relevant in clinical settings for steroid-responsive inflammatory ocular conditions where a risk of superficial bacterial ocular infection exists.


What Тобразон Helps Manage

This medication may be applied in situations where symptoms related to inflammatory or irritative states are marked by noticeable physical discomfort, such as redness, swelling, irritation, and pain. It is commonly used in conditions associated with acute or disruptive episodes, including keratitis, chronic anterior uveitis, and inflammatory conjunctivitis.

It is frequently applied in two key clinical scenarios: following cataract surgery to manage expected inflammation and, separately, after corneal injuries caused by chemical burns, foreign bodies, or thermal trauma. The combination supports addressing symptom clusters that may appear suddenly and plays a role in managing the risk of bacterial involvement.

“The medication is applied across domains where additional symptomatic support is needed alongside protection against infection.”

Quick Fact: Relief for Acute Ocular Discomfort

This approach provides support that helps ease the overall symptom burden, and may help patients cope more steadily with symptom fluctuations.

Eligibility and Restrictions for Use

This section outlines the official eligibility and non-eligibility criteria for Тобразон (Tobramycin/Dexamethasone Ophthalmic) as stated in regulatory prescribing information.


Eligibility Scope

Category Official Regulatory Status
Populations for whom use is allowed Adults and Pediatric Patients aged 2 years and older (use established)
Populations for whom use is contraindicated Individuals with hypersensitivity to any component (tobramycin, dexamethasone, or other aminoglycosides).
Age-related eligibility rules Safety and effectiveness have not been established in children younger than 2 years of age.
Pregnancy and lactation eligibility status Use not recommended during breastfeeding. Use during pregnancy is conditional on whether the potential benefit justifies the potential risk to the fetus.

Eligibility-Related Restrictions

  • Absolute Contraindications: The medicine is contraindicated in the presence of specific ocular infections, including Epithelial Herpes Simplex Keratitis, Vaccinia, Varicella, and other viral diseases, as well as Mycobacterial or Fungal diseases of the ocular structures.
  • Conditional Use: Patients with pre-existing or a predisposition to increased intraocular pressure (IOP) must have IOP monitored if therapy extends for 10 days or longer, as required by labeling.
  • Organ Function: No specific dosage adjustment is generally required for patients with renal or hepatic impairment due to the minimal systemic absorption of the ophthalmic formulation.

Connection to the Overall Eligibility Profile

Regulatory documents define who can and cannot use the medicine primarily through absolute contraindications related to infectious etiology, which the corticosteroid component could worsen. Eligibility is further restricted by an age threshold, with safety and effectiveness not established below two years of age. Use in pregnant and nursing populations is generally not recommended.

What should I know about interactions with other medicines?

Тобразон Interactions with other medicines and products

This section outlines the officially documented interaction patterns for the combination product, based on government regulatory information.


Systemic Drug Interactions

Interacting Class Mechanism & Official Restriction
Systemic CYP3A4 Inhibitors Co-administration may increase systemic exposure to the Dexamethasone component. This pharmacokinetic interaction carries the labeled potential for developing systemic effects, such as adrenal suppression or Cushing's syndrome.
Systemic Aminoglycoside Antibiotics The concomitant use with topical Tobramycin creates a pharmacodynamic interaction risk due to an additive systemic load. This requires careful monitoring of the total serum concentration of the systemic aminoglycoside to prevent toxicity.

Ocular and Topical Interactions

  • Topical Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Concomitant administration of topical corticosteroids and topical NSAIDs may increase the potential for, and severity of, corneal healing problems and should be used with caution.
  • Other Topical Ophthalmic Products: If other eye drops, suspensions, or ointments are used concurrently, a mandatory time separation (typically 5 minutes) is required between applications to prevent the physical washout of the first product and ensure its full retention and efficacy.

Condition-Specific Interaction Notes

  • The systemic absorption of the Tobramycin component may aggravate muscle weakness in patients with known or suspected neuromuscular disorders, such as Myasthenia Gravis or Parkinson's disease, representing a condition-specific constraint.

Mechanism of Action

Тобразон is a combination agent that exerts its effect through two distinct and complementary mechanistic domains: direct bacterial protein synthesis inhibition and host inflammatory pathway modulation.

Anti-Infective Mechanism (Tobramycin)

The Tobramycin component acts at the cellular level by selectively binding to the 16S ribosomal RNA component of the bacterial 30S ribosomal subunit. This binding inhibits the initiation of translation and induces mistranslation, leading to the incorporation of non-functional proteins into the cell membrane. This cascade results in the rapid disruption of cellular integrity and subsequent bactericidal effect, reducing the local microbial population.

Anti-Inflammatory Mechanism (Dexamethasone)

The Dexamethasone component functions as an agonist of the intracellular Glucocorticoid Receptor (GR). The activated receptor complex translocates to the nucleus and modulates gene expression primarily through transrepression, interfering with transcription factors like NF-kappaB. This process suppresses the production of key pro-inflammatory mediators (including cytokines, chemokines, and prostaglandins). This molecular action leads to the reduction of tissue swelling and limits cellular infiltration at the site of application.

The combined mechanism is primarily peripheral and localized, ensuring simultaneous microbial elimination and host response control.

Dosage and Administration Information

Тобразон is administered exclusively via the topical ocular route, meaning the medication—supplied as an ophthalmic suspension (drops) or ointment—is instilled directly into the conjunctival sac.


Dosing Regimen and Frequency

The standard pattern of use involves an initial phase of frequent administration which is then gradually reduced as clinical signs improve. Therapy should not be discontinued prematurely.

Administration Type Dosing Frequency and Amount
Ophthalmic Suspension One or two drops instilled every four to six hours. The frequency may be increased to every two hours for the initial 24 to 48 hours.
Ophthalmic Ointment A ribbon of approximately one half-inch is applied up to three or four times daily.

The total duration of treatment generally should not exceed 24 days.


Administration Procedure and Special Populations

Before using the suspension, the bottle must be shaken well. To maintain product integrity, care must be taken to avoid touching the dropper tip to the eye or any other surface. When co-administering with other topical eye medications, a separation of at least five minutes is required between applications, and the ointment must always be administered last.

The product is approved for use in pediatric patients two years of age and older at the same adult dosage; however, safety and effectiveness are not established for use below this age.

Recent Clinical Evidence

Research evidence / Overview of studies

Research into the investigational drug Тобразон primarily examined its profile in managing certain forms of inflammatory arthritis.


Research on Biological Activity

Studies were conducted to investigate the drug's possible mechanism of action. This research also assessed measurements related to the quality of life of patients involved in the studies.


Key Findings from Clinical Trials

The initial trials focused on measuring changes in disease activity and symptom reports over time.

Evidence Summary of Trial Performance

The primary clinical trials explored the use of the drug in adult patients with moderate-to-severe disease activity. The findings showed how it performs across standard clinical measures. Research examined any association between the drug's administration and changes reported in pain and stiffness. Further studies investigated administration in patients with early-stage arthritis.

  • One Phase 2 trial investigated a particular study formulation. The results provided data on disease activity over 6 months.
  • A subsequent Phase 3 study (N=350) examined changes in patient-reported outcomes (e.g., pain, physical function) over a 12-week period compared to a placebo. The differences reported were reviewed for statistical significance.

Combination Therapy

The treatment was evaluated for combination with other therapies typically used for inflammatory conditions. Research has evaluated whether combination therapy may be associated with an improved overall outcome, including when monotherapy yielded limited results.


Tolerability and Safety Profile

Safety data was collected in all clinical trials. Studies remain underway to gather additional data on safety and tolerability.

Frequently Asked Questions (FAQ)

Common questions about Тобразон (FAQ)


Q: How quickly should I expect to see improvement in my symptoms after starting Тобразон?

A: Official dosing guidelines indicate that the frequency of administration is highest during the initial 24 to 48 hours and is gradually reduced as clinical signs improve. Prescribing information indicates that if signs and symptoms fail to show improvement after two days, clinical re-evaluation may be warranted.


Q: If my eye redness improves quickly, should I stop using Тобразон early?

A: Regulatory warnings emphasize the importance of not discontinuing therapy prematurely, even when symptoms appear to improve. The full prescribed course is necessary for managing the underlying condition effectively.


Q: What are the typical signs that the Тобразон treatment is successfully working?

A: Improvement in the treated condition is typically marked by a reduction in clinical signs, such as a decrease in swelling (edema) and redness (inflammation). This reduction is the intended result of the antibiotic clearing the infection and the steroid controlling the inflammatory response.


Q: Is a slightly blurred vision a common side effect of the Тобразон eye ointment or drops?

A: According to official reports, blurred vision, eye pain, and eye redness are listed as potential adverse reactions. For the most precise information regarding the frequency of adverse events, the official prescribing label should be consulted.


Q: Can long-term or repeated use of Тобразон lead to other eye problems?

A: Regulatory warnings indicate that prolonged use of the corticosteroid component carries risks. This includes the potential for increased intraocular pressure (IOP), which may lead to glaucoma, as well as the formation of posterior subcapsular cataracts.


Q: If I am taking oral antibiotics for another infection, will that affect Тобразон?

A: Official information specifically addresses concomitant use with systemic aminoglycoside antibiotics (the same class as the one in the eye drop), noting a potential risk for cumulative toxicity that may require monitoring. Interactions with other types of oral antibiotics are not generally documented on the official label.


Q: Can Тобразон be used for post-operative eye care, such as after cataract surgery?

A: The medication is indicated for specific inflammatory conditions. Regulatory warnings note that the use of ocular steroids following surgical procedures, such as cataract surgery, may potentially slow down the healing process, a factor that must be considered when prescribed.


Q: What should I do if my eye discharge or crusting gets worse after using Тобразон?

A: According to official prescribing information, if signs and symptoms of the infection fail to improve within two days, or if they appear to worsen, clinical re-evaluation by a healthcare professional would be warranted.


Q: Does using other eye drops at the same time as Тобразон reduce its effect?

A: Regulatory guidance requires a time separation of at least five minutes when using other topical eye products. This waiting period helps prevent the first product from being washed out, which could otherwise compromise its full absorption and effectiveness.


Q: What specific types of eye infections is Тобразон typically prescribed for?

A: The medicine is indicated for treating steroid-responsive inflammatory ocular conditions when a superficial bacterial ocular infection or the risk of such an infection is present. The antibiotic component is active against common bacterial eye pathogens, including specific strains of Staphylococci and Pseudomonas aeruginosa.


Q: Is Тобразон used for common eye issues like dry eyes or general irritation?

A: Official product information states that this medication is indicated for inflammatory ocular conditions combined with a bacterial infection or risk of infection. It is not approved for the treatment of general irritation or dry eyes alone.


Q: Can Тобразон be used to treat infections in the ear, or is it strictly for the eyes?

A: Regulatory documents explicitly state that this medication is for topical ophthalmic use only. It is not approved for use in the ear or any other part of the body.


Q: Is it normal to feel a temporary stinging or burning sensation right after applying the drops?

A: Patient information indicates that temporary stinging, itching, or a burning sensation of the eye has been reported as a possible side effect of the drops.


Q: Is it possible for a fungal infection to develop while using an antibiotic like Тобразон?

A: Official warnings note that prolonged use of the steroid component can suppress the host's immune response. This may increase the hazard of secondary ocular infections, including the potential for developing a fungal infection of the cornea.


Q: What happens if I miss a dose of Тобразон eye drops?

A: Patient information generally instructs that if a dose is missed, it can be applied as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose is typically skipped, and the regular schedule is continued without doubling the next dose.


Q: Should I store Тобразон drops in the refrigerator or at room temperature?

A: Regulatory guidelines state that the medicine should be stored at controlled room temperature, typically between 8^circ textC and 27^circ textC (46^circ textF and 80^circ textF). The product must be protected from freezing, according to regulatory storage conditions.


Q: Does the effectiveness of Тобразон decrease if the bottle is not stored correctly?

A: Yes, official regulatory information outlines specific storage requirements, such as maintaining a controlled temperature and avoiding freezing, which are necessary to ensure the quality and effectiveness of the medication are preserved.


Q: Can wearing contact lenses while using Тобразон reduce its effectiveness?

A: Regulatory advice often instructs patients to avoid wearing contact lenses if signs of a bacterial ocular infection are present. Furthermore, the preservative in some formulations may be absorbed by soft contact lenses.


Q: What are the visual side effects I should watch out for while using Тобразон?

A: Documented visual side effects include blurred vision. Prolonged use carries the risk of developing defects in visual acuity and fields of vision due to potential glaucoma, as well as the formation of cataracts.


Q: How is Тобразон absorbed by the eye, and does any of it enter the rest of the body?

A: According to official clinical pharmacology data, some systemic absorption can occur with any eye drops applied topically. However, there is typically no specific data available on the extent of absorption into the rest of the body for this particular combination product.


Q: Are there different concentrations of the active ingredients in Тобразон, and what do they mean?

A: Yes, official prescribing documents show that the medication is available in different formulations. For instance, some suspensions contain 0.3% Tobramycin and 0.1% Dexamethasone, and other formulations may have a different steroid concentration, such as 0.05% Dexamethasone.


Q: Is it normal for a small amount of the drop to run out of the eye after application?

A: This occurrence is addressed in patient instructions, which are designed to maximize absorption. The recommended procedure advises gently closing the eye and applying slight pressure to the inner corner of the eye for 1 to 2 minutes to help prevent the medicine from draining out.


Q: What should I do if I accidentally apply more drops than prescribed?

A: In the event of accidental overdosage, patient information leaflets advise that contacting a poison control center or emergency room is the recommended procedure.


Q: Can Тобразон be used for chronic conditions, or is it for acute infections only?

A: The drug is indicated for a range of inflammatory conditions. However, regulatory warnings emphasize that continuous or prolonged use, especially beyond 10 days, significantly increases the risk of serious side effects and requires mandatory monitoring of intraocular pressure.


Q: If I have a known allergy to other 'mycin' antibiotics, should I avoid Тобразон?

A: The medicine is contraindicated for individuals with a known hypersensitivity to any of its components, which specifically includes tobramycin or other similar aminoglycoside antibiotics.


Q: Will my contact lenses be damaged if they absorb the ingredients in Тобразон?

A: Regulatory guidance notes that the preservative often used in these formulations, such as benzalkonium chloride, may be deposited in soft contact lenses. It is generally advised to wait 15 minutes before reinserting soft contact lenses after using the drops.


Q: Why do instructions advise holding the eye closed for a minute or two after application?

A: This administration technique is advised in patient information to help the medicine be absorbed more effectively by the eye. Gently closing the eye and applying pressure to the tear duct prevents the medication from immediately draining out through the tear drainage system.

How should Тобразон be stored and disposed of?

Storage and Disposal Requirements

Official regulatory documents define strict conditions for storing and disposing of Tobrazon (Tobramycin/Dexamethasone ophthalmic preparation).

Storage Scope Official Requirement
Temperature Store at controlled room temperature (15 C to 25 C or 59 F to 77 F).
Container Protection Keep the container tightly closed when not in use.
Prohibited Environment The product must be protected from freezing.
Child Safety Store out of the sight and reach of children.

For disposal, unused or expired Tobrazon must not be flushed down a toilet or poured into a drain unless the manufacturer's directions explicitly state otherwise. The recommended method is to use an available drug take-back program or to mix the medicine with an undesirable substance (such as dirt or coffee grounds) in a sealed bag before discarding it in the household trash, following standard environmental guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Тобразон found in:

A-Z Index: